Pages

Sunday, January 14, 2018

Quick intro -- Nuzzel's news research tool

Hey Molecularfuture,

Nuzzel Media Intelligence is now available to everyone.

You can test it for free on your own industry or topic at:
http://nuzzel.com/intelligence

Nuzzel Media Intelligence scans and ranks tens of thousands of news sources daily, to find you highly relevant intelligence for you or your team.

Thanks!
Jonathan Abrams
CEO, Nuzzel, Inc.
unsubscribe
Nuzzel, Inc., 665 3rd St., Suite 150, San Francisco, CA 94107

Thursday, February 19, 2015

Tim Gallagher shared an article with you from Pocket

 
 
 
Tim Gallagher shared with you:
 
 
  Wild clinical success stats here  
 
 
 
  Forget the tech bubble. It's the biotech bubble you should worry about – Quartz  
 
  qz.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Sunday, November 30, 2014

Tim Gallagher shared an article with you from Pocket

 
 
 
Tim Gallagher shared with you:
 
 
  Eye-opening  
 
 
 
  The Case Against Early Cancer Detection  
 
  fivethirtyeight.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Thursday, November 6, 2014

Tim Gallagher shared an article with you from Pocket

 
 
 
Tim Gallagher shared with you:
 
 
  Very exciting and very close to fruition. (Except Theranos.)  
 
 
 
  10 Ideas That Are About To Change Medicine Forever  
 
  businessinsider.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Wednesday, March 12, 2014

Tim Gallagher shared an article from Pocket: Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes

 
 
 
Tim Gallagher shared with you:
 
 
  Here's a view inside drug partnering, with the main point being that Big Pharma is much more open to collaboration. That isn't news to most, but still good personal insights in the article. I'm surprised, though at one of the stats in the article: 33% of all Big Pharma leads are in-licensed. Put another way, 2/3rds of all Big Pharma programs are still internally sourced. That doesn't seem right - internal discovery in Big Pharma seems to me to have shrunken to a minority activity - maybe 25% of all big Pharma R&D. What's your impression?  
 
 
 
  Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes  
 
  online.wsj.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket